INMUNOTEKs prediction for immunotherapies in 2021 and beyond in the era of mass vaccinations

If mass vaccination can control the spread of SARS-CoV-2, as can be expected, our prediction for the business in 2021 is quite good. Although in many countries the economic damage caused by lock-downs and restrictions has been enormous, this has not been the case in other or in all sectors, as exemplified by the pharma sector. However, once the pandemic is over, short and medium-term strong financial problems derived from COVID-19 can affect all business in some way, or another, during the following years.

The subsector of immunotherapies, including vaccines, has been reinforced globally by the challenge posed by COVID-19. A vast majority of people believe that having effective vaccines is the definitive solution to the current pandemic. The speed with which an effective vaccine against SARS-CoV-2 has been obtained using synthetic mRNA platforms, a task considered impossible in less than a year, besides an outstanding achievement, may represent a new era in vaccinology to urgently control a new virus outbreak. On the other hand, vaccines developed with more conventional platforms will be authorized in 2021 and the following years. This will make available a wide range of alternatives in terms of efficacy, safety and immunogenicity in the medium and long term.